Triple-negative breast cancer: an update on neoadjuvant clinical trials.
Triple-negative breast cancer: an update on neoadjuvant clinical trials.
复制标题
DOI：
10.1155/2012/385978
复制
发表时间：
2012
影响因子：
1.9
通讯作者：
Anders CK
中科院分区：
文献类型：
--
作者：
Amos KD;Adamo B;Anders CK
三阴性乳腺癌(TNBC)是一种侵袭性的恶性肿瘤，尽管对化疗的反应率很高，但预后很差。这种情况突出表明，需要开发新的疗法和/或治疗战略，以降低与TNBC相关的死亡率。与传统辅助剂设置相比，新辅助剂设置提供了一个快速评估治疗效果的模型，患者应计费用更少，时间更短。此外，在这种情况下，已经存在一个明显的生存期改善的替代终点，即病理完全反应。在这里，我们回顾了已完成和正在进行的TNBC新辅助临床试验的最新数据。
Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.